Assessing the effect of fibromyalgia on patients’ sexual activity

Ryan, Sarah; Hill, Jackie; Thwaites, Cath; Dawes, P. T.

doi:10.7748/ns2008.09.23.2.35.c6669

Cited by 30 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sexual dysfunction can interfere in the quality of life and aggravate FM symptoms and depression, a frequent comorbidity of FM. The pathophysiological mechanisms seem to involve the peripheral and central nervous systems, hormones and/or immune-inflammatory mediators 4,8,9 , and hormonal variation associated with stress and the climacteric syndrome 16,17 . The search for clinical evidence is necessary to understand the role of comorbidities in FM and new possible approaches to assess these patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters

Zakka

Teixeira

Kaziyama

et al. 2016

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Fibromyalgia (FM) is characterized by chronic pain and comorbidities. Objective To investigate sexuality and depression in women with FM compared with controls and to correlate the findings with hematological parameters. Methods 33 women with FM and 19 healthy women were included and evaluated with the following instruments: Female Sexual Function Index, Beck Inventory, Visual Analogue Scale, medical history and laboratory exams. Results The prevalence of sexual dysfunction (P = 0.007) and depression (P < 0.001) were higher in the study group than in the control group; they were positively correlated (P = 0.023). The study group showed lower serum concentrations of testosterone, free T4, antinuclear factor, and lower blood hemoglobin and hematocrit. Conclusions FM was associated with high scores of sexual dysfunction and depression, and there were correlations with hematological parameters. We suggest the involvement of immune-inflammatory mediators and FM, which need further investigation to understand their role in FM syndrome and its comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Fibromyalgia patients have also sexual dysfunction 1,4,5,6 and reproduction problems 5 , as well as depression 7 . The mechanisms are unclear but seem to involve the hypothalamus-pituitary-adrenal axis, sexual hormones and cytokines 8 .…”

Section: Introductionmentioning

confidence: 99%

Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters

Zakka

Teixeira

Kaziyama

et al. 2016

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Fibromyalgia syndrome can affect the quality of life via induction of functional impairment [14]. Its prevalence is estimated to range between 2% and 4% [15][16][17][18]. It is observed in 3.4%-4.9% of females and 0.5%-1.6% of male patients with a female/male ratio of 6-9/1 [15,19].…”

Section: Discussionmentioning

confidence: 99%

“…Patients with AHI of ≥5 events/h were diagnosed with OSAS. Based on their AHI scores, the patients were categorized into mild (AHI, 5-15), moderate (AHI, [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30], and severe OSAS (AHI, >30) groups according to the AASM Task Force criteria [11]. Oxygen desaturation index (ODI) was defined as the total number of measurements of oxyhemoglobin desaturation of ≥4% within ≥10 s-<3 min from the baseline divided by the total sleep time.…”

Section: Psg Evaluationmentioning

confidence: 99%

Is There a Link Between Obstructive Sleep Apnea Syndrome and Fibromyalgia Syndrome?

et al. 2017

View full text Add to dashboard Cite

OBJECTIVES:Fibromyalgia syndrome (FMS) is characterized by complaints of chronic musculoskeletal pain, fatigue, and difficulty in falling asleep. Obstructive sleep apnea syndrome (OSAS) is associated with symptoms, such as morning fatigueness and unrefreshing sleep. We aimed to investigate the presence of OSAS and objectively demonstrate changes in sleep pattern in patients with FMS. MATERIAL AND METHODS:Polysomnographic investigations were performed on 24 patients with FMS. Patients were divided into two groups: patients with and without OSAS (Group 1 and Group 2, respectively). A total of 40 patients without FMS who presented to the sleep disorders polyclinic with an initial diagnosis of OSAS were included in Group 3. Based on their apnea hypopnea index (AHI), OSAS in the patients were categorized as mild (AHI,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15), moderate (30), or severe (>30). RESULTS:OSAS was detected in 50% of patients with FMS. The most prominent clinical findings were morning fatigue and sleep disorder, which were similar in three groups. In polysomnography (PSG) evaluation, patients with FMS had mild (33%), moderate (25%), and severe (42%) OSAS. In correlation analyses, negative correlations were observed between fibromyalgia impact questionnaire (FIQ) and mean oxygen saturation, visual analogue scale (VAS), and minimum oxygen saturation, whereas a positive correlation was found between FIQ and desaturation times in patients with FMS. CONCLUSION:Detection of OSAS in 50% of the patients with FMS, and similar rates of complaints of sleep disorder and morning fatigue of OSAS and FMS cases are important results. Detection of correlation between the severity of hypoxemia and FIQ and VAS scores are significant because it signifies the contribution of increased tissue hypoxemia to the deterioration of clinical status. Diagnosis and treatment of OSAS associated with FMS are important because of their favorable contributions to the improvement of the clinical picture of FMS. KEYWORDS:Obstructive sleep apnea syndrome, fibromyalgia syndrome, polysomnography, sleep disorders, apnea hypopnea index, hypoxemia INTRODUCTIONFibromyalgia syndrome (FMS) is a chronic health problem that presents with pain all over the body, with other symptoms, such as tenderness of the affected joints, muscles fatigue, sleep problems (waking up unrefreshed and excessive daytime sleepiness), and cognitive impairment [1]. Since its etiology is not fully known, its treatment is symptomatic. Patients with FMS are usually treated with various combinations of physiotherapy, psychotherapy, psychotrophic drugs, and analgesics. Treatment effectiveness in FMS is limited, and these patients frequently lead their lives with symptoms of chronic insomnia, sleep problems, fatigue, and pain [2].Obstructive sleep apnea syndrome (OSAS) is a pathology with systemic effects that are characterized by associated symptoms of recurrent episodes of upper respiratory tract obstruction, hypoxemia, arousals during sleep, morning fatigue because of impaired sleep ...

show abstract

“…En mujeres con fibromialgia que recibían antidepresivos también presentaban una función sexual peor en las dimensiones de placer y deseo-interés (14,18). También otros AD usualmente utilizados como coadyuvantes en dolor neuropático de constatada evidencia (4) por sus secundarismos en la respuesta sexual como la amitriptilina o la carbamazepina, no hemos conseguido demostrarlo.…”

unclassified

Sexo y dolor: la satisfacción sexual y la función sexual en una muestra de pacientes con dolor crónico benigno no pélvico

Gallach¹,

Juan²,

García‐Blanco³

et al. 2018

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Assessing the effect of fibromyalgia on patients’ sexual activity

Abstract: The symptoms associated with fibromyalgia had a negative effect on sexual enjoyment. The questionnaire appears to be useful in addressing sexuality in patients with fibromyalgia.

Cited by 30 publications

References 0 publications

Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters

Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters

Is There a Link Between Obstructive Sleep Apnea Syndrome and Fibromyalgia Syndrome?

Sexo y dolor: la satisfacción sexual y la función sexual en una muestra de pacientes con dolor crónico benigno no pélvico

Contact Info

Product

Resources

About